Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting

Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as im...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2024-05, Vol.17 (1), p.29-7, Article 29
Main Authors: Kang, Yun, Li, Chenggong, Mei, Heng
Format: Article
Language:English
Subjects:
Antigens
Cancer
Cell therapy
Chimeric antigen receptors
Comparative analysis
Correspondence
Cytokines
Cytotoxicity
Genes
Genetic engineering
Genome editing
Genomes
Graft versus host disease
Graft-versus-host reaction
Humans
Immune system
Immunotherapy, Adoptive - methods
Leukemia
Leukemia, B-Cell - immunology
Leukemia, B-Cell - therapy
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphoma
Lymphoma, B-Cell - immunology
Lymphoma, B-Cell - therapy
Malignancy
Medical research
Medicine, Experimental
Patients
Receptors, Chimeric Antigen - immunology
Receptors, Chimeric Antigen - therapeutic use
T cell receptors
T cells
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as immediate accessibility for patients, stable quality due to industrialized manufacturing and additional infusions of CAR-T cells with different targets. However, critical challenges, including graft-versus-host disease and CAR-T cell elimination by the host immune system, still require extensive research. The most common technological approaches involve modifying healthy donor T cells via gene editing technology and altering different types of T cells. This article summarizes some of the latest data from preclinical and clinical studies of off-the-shelf CAR-T cell therapies in the treatment of R/R B-cell malignancies from the 2023 ASH Annual Meeting (ASH 2023).
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-024-01550-9